The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026. The indirect holdings (486,777 shares) are maintained via the P.

MBX Biosciences targets endocrine and metabolic disorders with novel peptide therapies, advancing candidates across several ...

Positive results from MBX 1416 Phase 1 trial support Phase 2 advancement: In January 2025, the Company announced positive topline results from its Phase 1 single ascending dose and multiple ascending ...

$240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, ...

Metabolex announced positive results from two Phase 1 clinical trials of MBX-2982 for the treatment of type 2 diabetes. Both studies enrolled patients with pre-diabetes. Study 1 investigated the ...

MBX Biosciences MBX, a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, set terms for its initial public offering on Monday, with plans to offer 8.5 ...

Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candidate into ...

MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to ...

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 ...

Microbix Biosystems Inc. Annual stock financials by MarketWatch. View the latest MBX financial statements, income statements and financial ratios.